{"id":92,"date":"2020-04-21T08:45:32","date_gmt":"2020-04-21T08:45:32","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=92"},"modified":"2020-05-12T05:59:14","modified_gmt":"2020-05-12T05:59:14","slug":"03-april-2020-ivermectin-5000-fold-reduction-in-viral-rna-at-48h-during-in-vitro-studies","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/03-april-2020-ivermectin-5000-fold-reduction-in-viral-rna-at-48h-during-in-vitro-studies\/","title":{"rendered":"(03 April 2020) Ivermectin- 5000 fold reduction in viral RNA at 48h during in-vitro studies"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Ivermectin- inhibits the replication of SARS-CoV-2 in vitro<\/p>\n<p class=\"\"><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0166354220302011\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0166354220302011<\/a><\/p>\n<p class=\"\">Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activityin vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ivermectin- inhibits the replication of SARS-CoV-2 in vitro https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0166354220302011 Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activityin vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/03-april-2020-ivermectin-5000-fold-reduction-in-viral-rna-at-48h-during-in-vitro-studies\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(03 April 2020) Ivermectin- 5000 fold reduction in viral RNA at 48h during in-vitro studies&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,16],"tags":[38],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/92"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=92"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/92\/revisions"}],"predecessor-version":[{"id":93,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/92\/revisions\/93"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=92"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=92"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=92"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}